利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

403 条记录 (耗时 0.11 秒)

    Human tumor necrosis factor receptor TR10
    51.
    发明授权
    Human tumor necrosis factor receptor TR10 失效
    人肿瘤坏死因子受体TR10

    公开(公告)号：US06607726B1

    公开(公告)日：2003-08-19

    申请号：US09769402

    申请日：2001-01-26

    申请人： Jian Ni ,  Craig A. Rosen

    发明人： Jian Ni ,  Craig A. Rosen

    IPC分类号： A61K3900

    CPC分类号： C07K14/70578 ,  A61K38/00 ,  C12N2799/026

    摘要： The present invention relates to a novel protein, TR10, which is a member of the tumor necrosis factor (TNF) receptor superfamily and the TRAIL receptor subfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR10 protein. TR10 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR10 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体超家族和TRAIL受体亚家族成员的新蛋白质TR10。 特别地，提供编码人TR10蛋白的分离的核酸分子。 还提供TR10多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定TR10活性的激动剂和拮抗剂的筛选方法。

    Interleukin-19
    53.
    发明授权
    Interleukin-19 有权
    白细胞介素-19多肽及其变体

    公开(公告)号：US06583270B2

    公开(公告)日：2003-06-24

    申请号：US09386380

    申请日：1999-08-31

    申请人： Craig A. Rosen ,  Joseph J. Kenny

    发明人： Craig A. Rosen ,  Joseph J. Kenny

    IPC分类号： C07K1454

    CPC分类号： C07K14/54 ,  A61K38/00 ,  Y02A50/41

    摘要： The present invention concerns a novel human cytokine. In particular, isolated nucleic acid molecules are provided encoding interleukin-19 (IL-19). IL-19 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further concerns therapeutic methods for modulating cytokine production.

    摘要翻译： 本发明涉及一种新的人细胞因子。 特别地，提供编码白细胞介素-19（IL-19）的分离的核酸分子。 还提供了IL-19多肽，载体，宿主细胞以及用于制备它们的重组方法。 本发明还涉及调节细胞因子产生的治疗方法。

    Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
    55.
    发明授权
    Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides 失效
    编码前列腺生长因子的多核苷酸和产生前列腺生长因子多肽的方法

    公开(公告)号：US06521227B1

    公开(公告)日：2003-02-18

    申请号：US09461418

    申请日：1999-12-18

    申请人： Peter L. Hudson ,  Craig A. Rosen ,  Wei Wu He

    发明人： Peter L. Hudson ,  Craig A. Rosen ,  Wei Wu He

    IPC分类号： A61K3942

    CPC分类号： C07K14/575 ,  A61K39/00 ,  C07K16/22

    摘要： The present invention relates to human PGF polypeptides, DNA (RNA) encoding such polypeptides, and antibodies specifically binding such polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques, and for producing antibodies and antagonist/inhibitors against such polypeptides. Also provided are methods of using the polypeptide therapeutically for treating prostate cancer, promoting tissue regeneration, and facilitating wound healing. Further provided are methods of using such antibodies therapeutically to inhibit the action of PGF polypeptides and for the treatment of PGF-dependent tumors. Also provided is a diagnostic assay to detect prostate cancer and benign prostatic hyperplasia.

    摘要翻译： 本发明涉及人PGF多肽，编码这种多肽的DNA（RNA）和与这些多肽特异性结合的抗体。 还提供了通过重组技术产生这种多肽的方法，以及用于产生抗这种多肽的抗体和拮抗剂/抑制剂。 还提供了用于治疗前列腺癌，促进组织再生和促进伤口愈合的方法。 进一步提供的是使用这种抗体治疗性地抑制PGF多肽的作用和用于治疗PGF依赖性肿瘤的方法。 还提供了用于检测前列腺癌和良性前列腺增生的诊断测定法。

    Human endothelin-bombesin receptor antibodies
    56.
    发明授权
    Human endothelin-bombesin receptor antibodies 有权
    人内皮素 - 铃蟾肽受体抗体

    公开(公告)号：US06518404B1

    公开(公告)日：2003-02-11

    申请号：US09520210

    申请日：2000-03-07

    申请人： Yi Li ,  Craig A. Rosen ,  Chandrika Kumar

    发明人： Yi Li ,  Craig A. Rosen ,  Chandrika Kumar

    IPC分类号： C07K1628

    CPC分类号： C07K14/70571 ,  A61K38/00 ,  C07K14/72 ,  C07K14/723 ,  C12N2799/026

    摘要： A human endothelin-bombesin receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for disclosed. Also disclosed are methods for utilizing such polypeptide for identifying agonists and antagonists to such polypeptide. Agonists to the endothelin-bombesin receptor polypeptide of the present invention may be used to treat asthma, Parkinson's Disease, acute heart failure, hypotension and osteoporosis. Antagonists against such polypeptides may be used therapeutically to treat hypertension, ulcerigenesis, subarachnoid hemorrhage, asthma, tumors, ciclosporin toxicity, cancer and septic shock. Also disclosed are diagnostic methods for detecting mutations in the polynucleotides of the present invention and for detecting levels of the soluble polypeptides in samples derived from a host.

    摘要翻译： 人内皮素 - 铃蟾肽受体多肽和编码这种多肽的DNA（RNA）和用于公开的方法。 还公开了利用这种多肽识别这种多肽的激动剂和拮抗剂的方法。 本发明的内皮素 - 铃蟾肽受体多肽的激动剂可用于治疗哮喘，帕金森病，急性心力衰竭，低血压和骨质疏松症。 抗这种多肽的拮抗剂可以治疗性地用于治疗高血压，溃疡发生，蛛网膜下腔出血，哮喘，肿瘤，环孢菌素毒性，癌症和败血性休克。 还公开了用于检测本发明的多核苷酸中的突变并用于检测衍生自宿主的样品中可溶性多肽的水平的诊断方法。

    Death domain containing receptor-4 antibodies
    58.
    发明授权
    Death domain containing receptor-4 antibodies 有权
    含有受体-4抗体的死亡域

    公开(公告)号：US06461823B1

    公开(公告)日：2002-10-08

    申请号：US09448868

    申请日：1999-11-24

    申请人： Jian Ni ,  Craig A. Rosen ,  James G. Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    发明人： Jian Ni ,  Craig A. Rosen ,  James G. Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    IPC分类号： G01N33567

    CPC分类号： C07K14/70578

    摘要： The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新的含有死亡域的受体-4（DR4）蛋白。 特别地，提供编码人DR4蛋白的分离的核酸分子。 还提供了DR4多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定DR4活性的激动剂和拮抗剂的筛选方法。

    Human uridine disphosphate galactose-4-epimerase
    59.
    发明授权
    Human uridine disphosphate galactose-4-epimerase 失效
    人尿苷磷酸半乳糖-4-差向异构酶

    公开(公告)号：US06451577B1

    公开(公告)日：2002-09-17

    申请号：US09624183

    申请日：2000-07-24

    申请人： Hongjun Ji ,  Craig A. Rosen

    发明人： Hongjun Ji ,  Craig A. Rosen

    IPC分类号： C12N990

    CPC分类号： C12N9/90

    摘要： A human UDP galactose-4-epimerase polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the treatment of galactosemia. Also disclosed are diagnostic assays for the detection of mutations in the nucleic acid sequencing encoding human UDP galactose-4-epimerase protein and for detecting an altered level of human UDP galactose-4-epimerase protein in a sample derived from a host.

    摘要翻译： 公开了人类UDP半乳糖-4-差向异构酶多肽和编码这种多肽的DNA（RNA）以及通过重组技术产生这种多肽的方法。 还公开了利用这种多肽治疗半乳糖血症的方法。 还公开了用于检测编码人UDP半乳糖-4-差向异构酶蛋白的核酸测序中的突变的诊断测定，并用于检测源自宿主的样品中人UDP半乳糖-4-差向异构酶蛋白的水平的变化。

    Death domain containing receptor-4
    60.
    发明授权
    Death domain containing receptor-4 有权
    死亡域含受体4

    公开(公告)号：US06433147B1

    公开(公告)日：2002-08-13

    申请号：US09565918

    申请日：2000-05-05

    申请人： Jian Ni ,  Craig A. Rosen ,  James G. Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    发明人： Jian Ni ,  Craig A. Rosen ,  James G. Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    IPC分类号： C07K14705

    CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/39541 ,  C07K14/70578 ,  C07K14/7151 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

    摘要： The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新的含有死亡域的受体-4（DR4）蛋白。 特别地，提供编码人DR4蛋白的分离的核酸分子。 还提供了DR4多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定DR4活性的激动剂和拮抗剂的筛选方法以及使用DR4多核苷酸和多肽的方法。